Search global stocks & ETFs...Ctrl K
Learn Mode
DXCM
Stock Profile
07-30
Recommended Metric
Score Card
Explore Scores Tab
4.43
Very Good
Valuation Score
Key Score
3.00
Average
Management
5.00
Very Good
Growth
2.00
Bad
Profitability
3.00
Average
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
5.00
Very Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending Jun 28, 2027
Current
$74.85
Baseline
High
$117.60
▲
57.11%
Avg
$88.00
▲
17.57%
Low
$75.75
▲
1.20%
Analyst Ratings based on 38 Analysts
Strong Buy
1539%
Buy
1847%
Hold
513%
Sell
000%
Strong Sell
000%
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. The company enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.Read More